<DOC>
	<DOCNO>NCT01127633</DOCNO>
	<brief_summary>This study open-label extension study Alzheimer 's patient complete participation either solanezumab Clinical Trial H8A-MC-LZAM ( NCT00905372 ) H8A-MC-LZAN ( NCT00904683 ) .</brief_summary>
	<brief_title>Continued Safety Monitoring Solanezumab Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Meets National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDS/ADRDA ) criteria probable Alzheimer 's Disease Has complete participation solanezumab Study LZAM Study LZAN 80 week Must continue reliable caregiver frequent contact patient entire study Must good vein access administer infusion Agrees participate study investigational compound duration participation Study LZAO Are currently enrol , discontinue within last 30 day , clinical trial involve investigational drug device offlabel use drug device ( study drug/device use study ) , concurrently enrol type medical research judge scientifically medically compatible study Meets LZAM LZAN discontinuation criterion end treatment LZAM LZAN study</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>